Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome-Reference-Cited by-同舟云学术

Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome

Published:2001-01 Issue:3 Volume:42 Page:329-337
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Dabaja Bouthaina S.,O'brien Susan M.,Kantarjian Hagop M.,Cortes Jorge E.,Thomas Deborah A.,Albitar Maher,Schlette Ellen S.,Faderl Stefan,Sarris Andreas,Keating Michael J.,Giles Francis J.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428190109064589

Reference18 articles.

1. Richter's syndrome in chronic lymphocytic leukemia

2. Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia

3. Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: A study of 25 cases

4. Richter's syndrome: Diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions;Clinical Lymphoma Myeloma and Leukemia;2024-07

2. Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon;Expert Review of Hematology;2024-05-03

3. Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience;Annals of Hematology;2024-01-22

4. Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials;Frontiers in Immunology;2023-11-23

5. SOHO State of the Art Updates and Next Questions | Treatment of Richter's Transformation;Clinical Lymphoma Myeloma and Leukemia;2023-11